Panacos Financial Statements From 2010 to 2026

PANC Stock  USD 0.0001  0.00  0.00%   
Panacos Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Panacos Pharmaceuticals' valuation are provided below:
Gross Profit
99 K
Market Capitalization
321.8 K
Revenue
99 K
Earnings Share
(0.01)
Quarterly Revenue Growth
(0.20)
We have found one hundred twenty available trending fundamental ratios for Panacos Pharmaceuticals, which can be analyzed and compared to other ratios and to its competitors. Investors should ensure to check out all of Panacos Pharmaceuticals' recent performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 1 M, whereas Enterprise Value is forecasted to decline to (3 M).

Panacos Pharmaceuticals Total Revenue

153,900

Check Panacos Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Panacos Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Total Revenue of 153.9 K or Research Development of 21.1 M, as well as many indicators such as Price To Sales Ratio of 22.04, Dividend Yield of 0.0 or PTB Ratio of 0.0799. Panacos financial statements analysis is a perfect complement when working with Panacos Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Panacos Stock
Check out the analysis of Panacos Pharmaceuticals Correlation against competitors.
For information on how to trade Panacos Stock refer to our How to Trade Panacos Stock guide.

Panacos Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets50.4 M64.1 M56.4 M
Pretty Stable
Other Current Liabilities2.8 M3.6 MM
Slightly volatile
Total Current Liabilities5.4 M6.6 M7.6 M
Slightly volatile
Total Stockholder Equity34.3 M33.2 M30.4 M
Pretty Stable
Other Liabilities679.2 K540.9 K640.8 K
Slightly volatile
Accounts Payable2.1 M3.4 M2.9 M
Very volatile
Cash28.1 M43.5 M35.9 M
Slightly volatile
Other Assets1.3 M1.4 M1.6 M
Slightly volatile
Long Term Debt22.7 M21.6 M18.3 M
Slightly volatile
Inventory1.3 M1.4 M1.6 M
Slightly volatile
Other Current Assets1.1 M1.2 M1.1 M
Slightly volatile
Total Liabilities32.4 M30.9 M26.9 M
Slightly volatile
Intangible Assets340.3 K358.2 K598 K
Slightly volatile
Common Stock371.2 K615.2 K510.9 K
Pretty Stable
Property Plant Equipment893.5 K940.5 K3.3 M
Slightly volatile
Short Term Investments10.1 M16.1 M13.3 M
Slightly volatile
Good Will318.4 K358.2 K391 K
Slightly volatile
Net Receivables176.4 K132.3 K155.7 K
Slightly volatile
Short and Long Term Debt288.2 K411.7 K343.2 K
Slightly volatile
Total Current Assets57.7 M61.1 M51 M
Slightly volatile
Short Term Debt288.2 K411.7 K343.2 K
Slightly volatile
Deferred Long Term Liabilities275.7 K381.8 K320.9 K
Slightly volatile

Panacos Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue153.9 K162 K2.6 M
Slightly volatile
Research Development21.1 M28.9 M24.6 M
Slightly volatile
Cost Of Revenue25.2 M33.7 M37.3 M
Slightly volatile
Selling General Administrative9.6 M14.8 M12.1 M
Slightly volatile
Gross Profit153.9 K162 K245.5 K
Slightly volatile
Total Operating Expenses30.5 M43.6 M36.2 M
Slightly volatile
Non Recurring1.1 M1.1 M3.1 M
Slightly volatile

Panacos Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditures41 K43.2 K402.5 K
Slightly volatile
Total Cash From Financing Activities23.2 M23.7 M19.8 M
Slightly volatile
Total Cashflows From Investing Activities14.3 M13.6 M15.3 M
Slightly volatile
Other Cashflows From Investing Activities14.4 M13.7 M15.6 M
Slightly volatile
Sale Purchase Of Stock871.2 K917.1 K7.1 M
Slightly volatile
Change In Cash7.5 M4.3 M4.8 M
Slightly volatile
Depreciation558 K618.7 K518.9 K
Slightly volatile
Change To Operating Activities1.1 M1.1 M1.2 M
Slightly volatile
Change To Netincome4.1 M4.3 M4.4 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio22.0420.9921.7416
Slightly volatile
PTB Ratio0.07990.130.1345
Very volatile
Days Sales Outstanding206268276
Pretty Stable
Book Value Per Share0.590.621.4715
Slightly volatile
Average Payables2.3 M1.4 M1.5 M
Pretty Stable
Capex To Depreciation0.0660.06950.1346
Slightly volatile
PB Ratio0.07990.130.1345
Very volatile
ROIC0.360.40.4386
Slightly volatile
Inventory Turnover14.6117.0215.3543
Slightly volatile
Days Of Inventory On Hand26.3722.224.1367
Slightly volatile
Payables Turnover7.59.199.5087
Pretty Stable
Average Inventory873.9 K919.9 K918.5 K
Slightly volatile
Research And Ddevelopement To Revenue132125130
Slightly volatile
Capex To Revenue0.260.240.2635
Pretty Stable
Cash Per Share1.071.121.3647
Slightly volatile
Days Payables Outstanding39.0441.145.0876
Slightly volatile
Income Quality0.580.750.8093
Slightly volatile
Intangibles To Total Assets0.07790.05650.0628
Slightly volatile
Current Ratio3.684.925.0562
Pretty Stable
Tangible Book Value Per Share0.590.621.4715
Slightly volatile
Receivables Turnover1.341.411.5938
Slightly volatile
Shareholders Equity Per Share0.590.621.4715
Slightly volatile
Debt To Equity0.810.770.7262
Slightly volatile
Capex Per Share0.0010.0010.3185
Slightly volatile
Average ReceivablesM5.6 MM
Slightly volatile
Revenue Per Share0.00370.00391.2937
Slightly volatile
Interest Debt Per Share0.40.421.6833
Slightly volatile
Debt To Assets0.420.40.359
Pretty Stable
Operating Cycle216268278
Pretty Stable
Price Book Value Ratio0.07990.130.1345
Very volatile
Price Earnings To Growth Ratio0.01590.01510.0158
Slightly volatile
Days Of Payables Outstanding39.0441.145.0876
Slightly volatile
Operating Profit Margin205195202
Slightly volatile
Company Equity Multiplier1.62.222.0059
Slightly volatile
Long Term Debt To Capitalization0.440.420.38
Very volatile
Total Debt To Capitalization0.480.460.4197
Pretty Stable
Return On Capital Employed0.620.760.8031
Pretty Stable
Debt Equity Ratio0.810.770.7262
Slightly volatile
Ebit Per Revenue205195202
Slightly volatile
Quick Ratio3.644.925.0507
Pretty Stable
Cash Ratio2.763.513.6101
Pretty Stable
Days Of Inventory Outstanding26.3722.224.1367
Slightly volatile
Days Of Sales Outstanding206268276
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.950.91.0161
Slightly volatile
Price To Book Ratio0.07990.130.1345
Very volatile
Fixed Asset Turnover0.190.20.1969
Slightly volatile
Debt Ratio0.420.40.359
Pretty Stable
Price Sales Ratio22.0420.9921.7416
Slightly volatile
Asset Turnover0.00350.00370.0275
Slightly volatile
Gross Profit Margin0.290.370.391
Pretty Stable
Price Fair Value0.07990.130.1345
Very volatile

Panacos Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market CapM993 K1.1 M
Very volatile

About Panacos Pharmaceuticals Financial Statements

Panacos Pharmaceuticals stakeholders use historical fundamental indicators, such as Panacos Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Panacos Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Panacos Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Panacos Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Panacos Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Revenue162 K153.9 K
Cost Of Revenue33.7 M25.2 M
Research And Ddevelopement To Revenue 125.45  131.72 
Capex To Revenue 0.24  0.26 
Ebit Per Revenue 195.11  204.87 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Panacos Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Panacos Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Panacos Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Panacos Pharmaceuticals Stock:
Check out the analysis of Panacos Pharmaceuticals Correlation against competitors.
For information on how to trade Panacos Stock refer to our How to Trade Panacos Stock guide.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Will Biotechnology sector continue expanding? Could Panacos diversify its offerings? Factors like these will boost the valuation of Panacos Pharmaceuticals. Anticipated expansion of Panacos directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Panacos Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(0.01)
Revenue Per Share
0.002
Quarterly Revenue Growth
(0.20)
Return On Assets
(0.53)
Return On Equity
(1.69)
Understanding Panacos Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Panacos's accounting equity. The concept of intrinsic value - what Panacos Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Panacos Pharmaceuticals' price substantially above or below its fundamental value.
It's important to distinguish between Panacos Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Panacos Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Panacos Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.